. 2022 Apr 1;10(4):832. doi: 10.3390/biomedicines10040832

Table 2.

Collection of non-ribosomal peptides proposed for CRC therapy.

Protein/Peptides	Bacterial Source	Mode of Action	Refs.
Lucentamycin	Nocardiopsis lucentensis	Shows cytotoxicity and induces apoptosis against HCT-116 CRC cells.	[99]
Arenamides	Salinispora arenicola	Subtypes A and B block TNF, nitric oxide and prostaglandin E2 and act cytotoxic on HCT-116 CRC cells. Investigation for chemopreventive and anti-inflammatory properties in HCT-116 CRC cells is proposed.	[100]
Ohmyungsamycins	Streptomyces sp.	Subtype A modulates Skp-p27 axis leading to cell cycle arrest (G0/G1 phase), apoptosis and selectively targeted reduction of proliferation in HCT-116 CRC cells.	[99,102]
Ohmyungsamycins	Streptomyces sp.	Subtype A shows stronger activity against human cancer cells compared to subtype B.	[106]
Mixirins	Marine Bacillus sp.	Subtypes A, B and C act cytotoxic against cancer cells and inhibit cell growth in HCT-116 CRC cells.	[103]
Urukthapelstatin	Mechercharimyces asporophorigenens	Subtype A inhibits DNA synthesis, growth and proliferation of HCT-116 CRC cells.	[104]